Luteolin |
Catalog No.GN10370
One-Click Copy Product Info
|
Luteolin is a flavonoid compound with multiple functions such as anti-inflammatory, antioxidant, and anti-cancer. Luteolin is an effective inhibitor of nuclear factor erythroid 2-related factor 2 (Nrf2).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 491-70-3
Sample solution is provided at 25 µL, 10mM.
Luteolin is a flavonoid compound with multiple functions such as anti-inflammatory, antioxidant, and anti-cancer[1, 2]. Luteolin is an effective inhibitor of nuclear factor erythroid 2-related factor 2 (Nrf2)[3].
In vitro, Luteolin (0-160µM) treatment of NCI-H460 cells for 24h inhibited cell viability in a concentration-dependent manner, induced cell cycle arrest at the S phase, increased the protein expression level of apoptosis regulatory proteins, and also inhibited cell migration[4]. Luteolin (0.05, 0.1, 5μM) treatment of rat bone marrow mesenchymal stem cells (BMSC) for 24-72h activated the PI3K/Akt signaling pathway and promoted BMSC osteogenic differentiation[5].
In vivo, oral administration of Luteolin (10, 25, 50, 100 mg/kg/day) to treat rats with nonalcoholic steatohepatitis (NASH) significantly reduced the levels of serum liver function biomarkers (ALT, AST, total bilirubin), hyaluronic acid, and malondialdehyde, and also reduced the levels of proinflammatory factors IFN-γ, TNF-α, IL-1α, and IL-18[6]. Luteolin (50, 100 mg/kg/day) to treat rats with cognitive impairment induced by infusion of Aβ (1-40) peptide significantly improved Aβ-induced spatial learning and spatial working memory impairment and cognitive impairment, increased the levels of SOD and GSH-Px in hippocampal homogenate, and reduced the level of MDA[7].
References:
[1] Coleta M, Campos M G, Cotrim M D, et al. Assessment of luteolin (3′, 4′, 5, 7-tetrahydroxyflavone) neuropharmacological activity[J]. Behavioural brain research, 2008, 189(1): 75-82.
[2] Ziyan L, Yongmei Z, Nan Z, et al. Evaluation of the anti-inflammatory activity of luteolin in experimental animal models[J]. Planta medica, 2007, 73(03): 221-226.
[3] Tang X, Wang H, Fan L, et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs[J]. Free Radical Biology and Medicine, 2011, 50(11): 1599-1609.
[4] Ma L, Peng H, Li K, et al. Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis[J]. Molecular medicine reports, 2015, 12(3): 4196-4202.
[5] Liang G, Zhao J, Dou Y, et al. Mechanism and experimental verification of luteolin for the treatment of osteoporosis based on network pharmacology[J]. Frontiers in Endocrinology, 2022, 13: 866641.
[6] Abu-Elsaad N, El-Karef A. Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1alpha by luteolin[J]. Pharmacological Reports, 2019, 71: 688-694.
[7] Yu T X, Zhang P, Guan Y, et al. Protective effects of luteolin against cognitive impairment induced by infusion of Aβ peptide in rats[J]. International Journal of Clinical and Experimental Pathology, 2015, 8(6): 6740.
| Cell experiment [1]: | |
|
Cell lines |
NCI-H460 cells |
|
Preparation Method |
Cells were seeded into 96 well plates and were treated with 0, 20, 40, 80 or 160µM luteolin for 24 h at 37°C. |
|
Reaction Conditions |
0, 20, 40, 80 or 160µM; 24h |
|
Applications |
Luteolin inhibits the viability of NCI-H460 cells in a concentration-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Wistar rats |
|
Preparation Method |
Rats were fed a high carbohydrate/high fat diet (30% carbohydrate and 42% fat) daily for 12 weeks to induce nonalcoholic steatohepatitis (NASH). Luteolin (10, 25, 50 or 100 mg/kg/day) was administered as a suspension (10% w/v in 0.9% NaCl) using an oral gavage. |
|
Dosage form |
10, 25, 50 or 100 mg/kg/day; p.o. |
|
Applications |
Luteolin to reduce activity of ALT and AST and to decrease levels of bilirubin, hyaluronic acid and malondialdehyde significantly. |
|
References: [1] Ma L, Peng H, Li K, et al. Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis[J]. Molecular medicine reports, 2015, 12(3): 4196-4202. [2]Abu-Elsaad N, El-Karef A. Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1alpha by luteolin[J]. Pharmacological Reports, 2019, 71: 688-694. |
|
| Cas No. | 491-70-3 | SDF | |
| Chemical Name | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one | ||
| Canonical SMILES | C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O | ||
| Formula | C15H10O6 | M.Wt | 286.24 |
| Solubility | DMF: 20 mg/ml,DMF:PBS (pH 7.2) (1:5): 1 mg/ml,DMSO: 10 mg/ml,Ethanol: 5 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4936 mL | 17.4679 mL | 34.9357 mL |
| 5 mM | 698.7 μL | 3.4936 mL | 6.9871 mL |
| 10 mM | 349.4 μL | 1.7468 mL | 3.4936 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)